Getting better mileage with logically primed CARs.

Although remarkably successful against liquid tumors, chimeric antigen receptor (CAR)-T cell therapy has been stymied by solid tumors, limited by inadequate specificity and poor efficacy. Pairing synthetic Notch (synNotch) receptors with CARs, Choe et al. and Hyrenius-Wittsten et al. engineer T cells that more precisely and potently combat solid tumors.
Competing Interests: Declaration of interests Y.Y.C. and A.J.H. are inventors on patent applications that are unrelated to the work discussed here but whose value may be affected by the publication of this work. L.C.C. declares no competing interests.
(Copyright © 2021 Elsevier Inc. All rights reserved.)